ARCHIVE

Antiphospholipid syndrome (APS) is a hypercoagulable state characterized by vascular thromboses, pregnancy morbidity and the presence of antiphospholipid antibodies (aPL), namely lupus anticoagulant, anticardiolipin antibodies and anti-beta 2 glycoprotein I (anti-β2GPI) antibodies. APS can clinically present with arterial and venous thrombotic manifestations and/or pregnancy morbidity as well as various non-classical manifestations such as heart valve abnormalities, thrombotic renal microangiopathy, skin involvement and thrombocytopenia. A small percentage (<1%) of patients with APS develop systemic, multiorgan life-threatening complications defined as catastrophic APS. Treatment mainly consists of anticoagulant and/or antiplatelet agents. The aim of the current project is to create a Greek Registry of consecutive patients with APS followed regularly in university centers with detailed recording of demographic, disease-related serological and clinical parameters, prevalence of comorbidities including traditional risk factors for thrombosis, infections and neoplasms, and the current and previous use of different antithrombotic or anti-inflammatory regimens.